Biolife Solutions (BLFS) EBIT (2010 - 2026)

Biolife Solutions (BLFS) has 17 years of EBIT data on file, last reported at $27000.0 in Q1 2026.

• EBIT for Q1 2026 came in at $27000.0, up 105.41% year-over-year; the trailing twelve-month figure through Mar 2026 was -$15.4 million (down 813.62% YoY), and the FY2025 annual result was -$16.6 million, down 270.83% from the prior year.
• EBIT slipped to $27000.0 in Q1 2026 per BLFS's latest filing, from $1.3 million in the prior quarter.
• Over five years, EBIT peaked at $90.3 million in Q4 2022 and troughed at -$76.6 million in Q2 2022.
• A 5-year average of -$2.8 million and a median of -$1.3 million in 2024 frame the typical range for EBIT.
• On a YoY basis, EBIT climbed as much as 589.29% in 2022 and fell as far as 1580.86% in 2022.
• A 5-year view of EBIT shows it stood at $90.3 million in 2022, then plunged by 80.6% to $17.5 million in 2023, then tumbled by 96.91% to $542000.0 in 2024, then surged by 148.52% to $1.3 million in 2025, then plunged by 98.0% to $27000.0 in 2026.
• Business Quant data shows BLFS's EBIT at $27000.0 in Q1 2026, $1.3 million in Q4 2025, and -$89000.0 in Q3 2025.